Form D · Biotechnology

Fulcrum Therapeutics, Inc.

Cambridge, MA · CIK 0001680581

Offering snapshot reported Jun 11, 2020 · SEC filing

Reported sold
$68.5M
Offering amount: $68.5M
Investors reported
13
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 9, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 11, 2020Initial$68,499,987No comparison13SEC filing
Sep 5, 2018Initial$80,000,000No comparison20SEC filing
Jul 25, 2017Amendment$29,666,666$12,666,666vs Jul 25, 20161SEC filing
May 10, 2017Initial$5,000,000No comparison1SEC filing
Jul 25, 2016Initial$17,000,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$4.11M
Finders' fees
$0
Form D file number
021-368703

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
SVB Leerink LLC39011

Source: Form D, filed Jun 11, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Diego Cadavid Executive
James Collins Director
Katina Dorton Director
Alan Ezekowitz Director
James Geraghty Director
Robert Gould Director, Executive
Amit Hasija Executive
Kate Haviland Director
Mark Levin Director
Bryan Stuart Executive
James Tananbaum Director
Owen Wallace Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
26 Landsdowne Street
Cambridge, MA, 02139